Research programme: cancer and CNS disorder therapeutics - Angiochem

Drug Profile

Research programme: cancer and CNS disorder therapeutics - Angiochem

Alternative Names: ANG 3201; ANG-1007; ANG-1009; ANG-1011; ANG-2002; ANG-2004; ANG-2008; ANG-3101; ANG-3202; ANG-4043; Angiopep-antibody-drug conjugate - Angiochem

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator AngioChem
  • Class Drug conjugates; Monoclonal antibodies; Peptides; Small molecules
  • Mechanism of Action Brain derived neurotrophic factor modulators; DNA intercalators; ERBB 2 receptor antagonists; Glucagon like peptide 1 receptor agonists; Immunomodulators; Leptin receptor modulators; Neurotensin receptor modulators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain metastases; Pain
  • Research Cancer
  • Discontinued Brain cancer; Diabetes mellitus; Neuroprotection; Obesity; Parkinson's disease

Most Recent Events

  • 08 Sep 2016 Early research in Cancer in Canada (Parenteral) before September 2016 (Angiochem Pipeline, September 2016)
  • 09 Dec 2014 Efficacy data from a preclinical trial in Brain metastases released by AngioChem
  • 18 Feb 2014 Preclinical pharmacokinetics and pharmacodynamics data in Pain released by Angiochem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top